Key Highlights

  • Nurix traded 41.91% lower at USD 15.00 intraday on November 4, 2026, from an implied prior close of about USD 25.82 (calculated).
  • Under a November 3, 2026 release, Sanofi chose to stop the Phase 1 study of SAR448272, an oral STAT6 degrader, and wind down the program.
  • Nurix does not expect milestones or royalties from that program. Cash of USD 1.1 billion as of August 31, 2026 supports operations into the second half of 2029.
  • Jefferies reportedly reduced its price target from USD 45 to USD 36 while maintaining a Buy rating, describing the choice as a surprise.

Intraday Move in Nurix Therapeutics (down USD 10.82, 41.91%)

Nurix Therapeutics (NASDAQ:NRIX) was 41.91% lower at USD 15.00 intraday on November 4, 2026, a decline of USD 10.82 from an implied prior close of about USD 25.82 (calculated). The sell-off intensified from roughly 28% in pre-market activity earlier that morning. Volume reached about 3.84 million shares, around 1.54 times normal per the intraday quote. The trigger appears to be a company release dated November 3, 2026, issued after the close, stating that partner Sanofi had decided to halt the Phase 1 first-in-human study of SAR448272 and end the program. The release did not disclose Sanofi's reasoning.

What the Sanofi Decision Changes

SAR448272 is an oral degrader directed at STAT6, a transcription Factor involved in allergic and inflammatory signaling. Nurix stated it no longer expects development, regulatory or commercial milestones or royalties from the compound, although it remains eligible for payments on other licensed programs that Sanofi may move forward. Sanofi exercised a license extension option in 2025 covering two transcription factor programs, and Nurix retains an option to co-develop and co-promote in the United States after clinical proof of concept. According to published coverage, Jefferies called the decision a surprise, said management had not seen supporting data, and noted that Sanofi cited no immediate patient safety concern. That same coverage put the Jefferies target cut from USD 45 to USD 36 with its Buy rating intact.

Cash, Pipeline and Remaining Risks

Nurix said cash, equivalents and marketable securities stood at USD 1.1 billion on August 31, 2026, and the runway into the second half of 2029 has not changed. The intraday quote implies a Market Value near USD 1.64 billion, so cash makes up a large portion of valuation, though spending continues. The lead asset, the BTK degrader bexobrutideg, is in a Phase 3 chronic lymphocytic leukemia trial with Roche, leaving the company reliant on a single partner. NX-1607, a CBL-B inhibitor, is in Phase 1b cohorts, and GS-6791 is in Phase 1 with Gilead. Partners can end early-stage programs with little notice, and partnered Revenue can vanish when they do. The release listed no upcoming catalysts, so near-term direction may hinge on how investors reassess the Partnership model after a sharp, news-driven repricing.

Where Things Stand

Nurix Therapeutics (NASDAQ:NRIX) is down 41.91% because Sanofi terminated the SAR448272 trial and program, removing a partnered asset along with its potential milestones and royalties, and no reason from Sanofi was given. The Balance Sheet and runway guidance are unchanged, and the Roche-partnered Phase 3 effort remains the principal value driver. Watch for any further commentary from Sanofi, the status of the second transcription factor program, updates on bexobrutideg and the next Quarterly Report from the company.